Skip to main content
SpringerLink
Log in

Highlights der 51. Jahrestagung der American Society of Hematology (ASH) 2009

  • Kongressbericht
  • Published:
Onkopipeline

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Corthals SL, Johnson DC, de Knegt Y, et al. Genetic associations with bortezomib mediated neuropathy in multiple myeloma. Blood 2009;114:ASH Meeting Abstracts:abstract 1794.

    Article  Google Scholar 

  2. Einsele H, Liebisch P, Langer C, et al. Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa trial). Blood 2009;114:ASH Meeting Abstracts:abstract 131.

    Google Scholar 

  3. Kuiper R, Corthals SL, Hanifi-Moghaddam P, et al. Developing a SNP classifier for predicting peripheral neuropathy by bortezomib in multiple myeloma patients. Blood 2009;114:ASH Meeting Abstracts:abstract 1800.

    Google Scholar 

  4. Lacy MQ, Gertz MA, Hayman SR, et al. Pomalidomide (CC4047) plus low dose dexamethasone (pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Blood 2009;114:ASH Meeting Abstracts:abstract 429.

    Google Scholar 

  5. Mateos MV, López-Corral L, Hernández MT, et al. Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (len/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis. Blood 2009;114:ASH Meeting Abstracts:abstract 614.

    Google Scholar 

  6. Mateos MV, Oriol A, Martinez J, et al. A prospective, multicenter, randomized, trial of bortezomib/ melphalan/prednisone (VMP) versus bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years. Blood 2009;114:ASH Meeting Abstracts:abstract 3.

    Article  Google Scholar 

  7. Niesvizky R, Wang L, Orlowski RZ, et al. Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM). Blood 2009;114:ASH Meeting Abstracts:abstract 304.

    Google Scholar 

  8. Palumbo A, Dimopoulos MA, Delforge M, et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. Blood 2009;114:ASH Meeting Abstracts:abstract 613.

    Google Scholar 

  9. Richardson P, Siegel D, Baz R, et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. Blood 2009;114:ASH Meeting Abstracts:abstract 301.

    Article  Google Scholar 

  10. Siegel D, Wang L, Orlowski RZ, et al. PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort. Blood 2009;114:ASH Meeting Abstracts:abstract 303.

    Google Scholar 

  11. Streetly M, Stewart O, Gyertson K, et al. Pomalidomide monotherapy for relapsed myeloma is associated with excellent responses and prolonged progression free and overall survival. Blood 2009;114:ASH Meeting Abstracts:abstract 3878.

    Google Scholar 

  12. Vij R, Wang L, Orlowski RZ, et al. Carfilzomib (CFZ), a novel proteasome inhibitor for relapsed or refractory multiple myeloma, is associated with minimal peripheral neuropathic effects. Blood 2009;114:ASH Meeting Abstracts:abstract 430.

    Google Scholar 

  13. Wang L, Siegel D, Kaufman JL, et al. Updated results of bortezomib-naïve patients in PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory Myeloma (MM). Blood 2009;114:ASH Meeting Abstracts:abstract 302.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin III, Hämatologie, Onkologie, Rheumatologie und Infektionskrankheiten, Universitätsklinikum Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany

    Stephan Stilgenbauer

Authors
  1. Stephan Stilgenbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephan Stilgenbauer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stilgenbauer, S. Highlights der 51. Jahrestagung der American Society of Hematology (ASH) 2009. Onkopipeline 3, 52–61 (2010). https://doi.org/10.1007/s15035-010-0181-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15035-010-0181-9

Search

Navigation